Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: prophet_often who wrote (23)	1/17/2001 7:03:42 PM
From: tuck	Read Replies (1) \| Respond to of 897

prophet_often, Thanks for your thoughts. I found the article confusing at first, because it seems to contradict itself in two adjacent sentences: " . . . $100 million in excess supply and increases in production yield led him to cut his 2001 sales figures by 16 percent to $808 million from $964 million. However, tightening Enbrel supplies are also a concern for Immunex as the year progresses." The only way this makes any sense is that Enbrel has little shelf life. Haven't researched that aspect. Do you know if that is so? Cheers, Tuck

To: prophet_often who wrote (23)	1/21/2001 3:38:35 PM
From: prophet_often	Read Replies (1) \| Respond to of 897

Covered IMNX short AH Friday at 33.125 for a four day 13% profit. AMGN news may cause a short term rally in the bios next week. Also did not want to hold IMNX short through earnings on Wed. Will look at this one again later. Still holding IVGN short from 71. Do not like the chart, nor do I like the valuation placed on this company. I understand they are having some problems integrating the LTEK merger. The high valuation placed on this company appears to be the result of future earnings growth projections priced into the stock. IMHO, this one is setting up for some disappointments down the road.